Crop Secures THC License Portfolio at New 1,000 Acre Farm for Cultivation, Extraction, Commercial Kitchen and Retail
Momentum Public Relations
Press Release: September 26, 2018
CROP INFRASTRUCTRE CORP. (CSE: CROP) (OTC: CRXPF) announces that its subsidiary Elite Ventures Group LLC has signed a joint venture agreement with The Hempire LLC of Nevada (the “Tenant”) to purchase a 100% interest in an 1,000 acre Esmeralda County agricultural cannabis project tenanted with a suite of cannabis licenses including medical cultivation, medical production and with adult use recreational cultivation & production conditional licenses as well as an option to acquire a retail dispensary application assigned to a strategic location on highway 95 on route to Las Vegas. CROP has agreed to loan up to $4,250,000 USD over a period of the next 6 months to acquire 100% of the initial 10 acres of real estate and associated infrastructure with the additional 1,000 acres being paid for at a cost of $4,500,000 over a 20-year amortization period at 6% interest with a 3-year balloon payment. CROP will receive preferential payback on the project at a rate of 60% of the net profits from Elite.
Esmerelda County is one of the only jurisdictions in Nevadawhere climate and zoning allows for greenhouse or outdoor growing. This will be significant for our tenant growers and brand licensee to be able to provide high quality product on a large scale at the lowest cost possible, keeping with CROP’s strategy.
The initial set up costs of outdoor 80-acre operation will be approximately $1,200,000 and should yield tenants 160,000 pounds of outdoor cannabis for extraction and edibles and a 44,000 square foot light supplemented greenhouse facility at a cost of $2.0 Million. The greenhouse facility should yield tenants 24,000 pounds of high quality flower per year with an additional 25% for extraction and edibles. The project can be expanded up to 300 acres of combined greenhouse and outdoor cultivation.
RBC Capital Markets, an investment bank that’s part of Royal Bank of Canada, issued a memo to clients outlining the rapid growth of the U.S. marijuana sector. The memo, authored by Nik Modi, shows how cannabis sales in the U.S. are gaining ground on beer and wine sales. Projecting a compound annual growth rate (CAGR) of 17 percent, Modi estimates that the legal cannabis category could reach $47 billion in sales annually in the United States within the next decade, according to Business Insider.
The Esmeralda Property
- 10 acres of land adjacent to Highway 95 outside of Tonopah
- 10 acre-feet of ground water rights
- Option to acquire 1,000 acres of contiguous property with water rights
- 2,400 sqft production, extraction, commercial kitchen facilities with state approval
- NV Energy Utility agreement for cultivation building and expansion to 12,000 sqft.
- Equipment included: Building, main HVAC system, lighting, backup generator, sinks, and restroom fixtures.
CROP Infrastructure Director and CEO, Michael Yorke, stated: “CROP now has over 1,000 acres for THC Cannabis cultivation, extraction, commercial kitchen and 1,865 acres for HEMP CBD production in Nevada. Our ambition has always been to be early mover and establish our market footprint in any jurisdiction we invest in. Next year CROP plans on having the largest real estate foot print in the State of Nevada with tenanted operations in the fast-growing CBD & THC markets.”
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, a 1,865 CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications. CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Disclaimer for Forward-Looking Information
Certain statements in this press release related to the Offering, the securities issuable thereunder and the Transaction are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected yield from The Esmeralda Property; the technological effects of The Esmeralda Property on production; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: http://www.cropcorp.com
Phone: +1-(604)-484-4206
- Published in Business, CROP Infrastructure, Medical Marijuana, News Home
MedX Health appoints Spearn as CEO, director
Momentum Public Relations
Press Release: September 24, 2018
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces the following changes to its Board and Executive team, effective immediately. Scott Spearn, who joined the Company as President in April 2018 is taking on the additional role of Chief Executive Officer and is joining the Board of Directors. Rob von der Porten, previously the CEO, has been appointed as Chairman of the Board in place of Gary Van Nest who has retired from that position and remains as a director.
“With the recent launch of our DermSecure™ telemedicine platform and anticipating a global roll-out of this leading product, the transition of Scott’s role to CEO represents a natural evolution at MedX,” noted Rob von der Porten, MedX’s new Chairman. “Scott’s experience in building sales organizations and developing international markets in the medical device field will help accelerate our growth from our SIAscopy technology and our Therapeutic and Dental Laser products.”
Gary Van Nest noted, “On behalf of the Board, we want to thank Rob von der Porten for his leadership during challenging times over the past few years and developing with the MedX team solid product roadmaps such as the delivery of DermSecure™.
“I am excited to be taking on the CEO role, leading a dedicated team of hard-working people. MedX is a great Canadian company with innovative products and robust technology that is making a big difference in the health of people’s lives around the world,” said Mr. Spearn.
Mr. Spearn is a seasoned medical device executive with nearly 30 years of developing sustainable, trusted relationships with key opinion leaders, strategic partners and industry influencers. Before joining MedX, Mr. Spearn held a number of senior executive roles at a multi-national medical device company where he substantially grew revenues across several business divisions.
The Company has granted 1,000,000 share options to the incoming CEO, the options having an exercise price of $0.16, exercisable for a period of five years, and vesting over a one-year period.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180924005812/en/
Contacts:
MedX Health Corp
Scott Spearn, 905-670-4428 ext 226
President and CEO
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com
- Published in Business, Life Sciences, MedX Health Corp., News Home, Technology
CROP Boosts Nevada CBD Farm to 1,865 Acres
Momentum Public Relations
Press Release: September 24, 2018
CROP Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) announced today that its subsidiary, Elite Ventures Group LLC, has signed a 3-year lease agreement for 800 additional acres of turn key pivot-irrigated agricultural property. The lease cost will be $550 USD per acre in 2019 and $700 USD per acre 2020 forward, paid quarterly commencing in March 2019. The property is in close proximity to CROP’s existing 1,065-acre Hemp CBD Farm in Nye County Nevada.
The combined Nevada properties, including the original one of 315 acres, have a total pivoted area of 1,340 acres but will require the installation of additional pivots and water wheels at a cost of $300,000 USD. Seasonal fertilizer, planting and seed costs are not expected to exceed $600,000 USD. All harvesting and commercial drying equipment have been paid for during the 2018 season.
According to cannabis industry analysts the Brightfield Group, it is estimated the hemp-CBD market alone could hit $22 billion by 2022.
The two existing strains planted during the 2018 season with approximately 12-19% CBD will be planted for 2019 along with 3 additional genetics in the same range of CBD. The farm will be planted and maintained to be organic to ensure the end product is to the specification of interested buyers.
CROP CEO, Michael Yorke, stated: “CROP is preparing for the upcoming Hemp Farming Act of 2018 which would remove hemp’s controlled substance designation, thus legalizing the crop under federal law, and allowing CBD isolate to be sold across all 50 states and exported internationally. As we enter the next phase of project development in Nevada we look forward to building our GMP extraction facility and introducing our made in America CBD Isolate to infuse in to our recently announced CannaDrink beverages and licensed topical lines.”
Yorke concluded: “CROP has the largest real estate foot print in Nevada dedicated to hemp-CBD. Once the additional upgrades are completed, we anticipate that our tenant and brand licensee will have 1,340 acres under irrigation. With two crops expected annually in 2019 we foresee a harvest potential of approximately 2,680,000 lbs of CBD flower. We expect to comfortably use funds from our 2018 harvest (next 30-60 days) to organically grow into the projects new foot print.”
CROP Nevada Hemp Initiatives For 2019
- Develop 300 acres additional pivots on newly leased land as per announced as per August 22, 2018
- Planting of 1,340 acres of High CBD Hemp strains
- Initial 1-ton per day processing capability GMP ISO 9000 extraction facility for pharmaceutical grade CBD
Hemp Farming Act of 2018
The Bill, supported by Senate Majority Leader Mitch McConnell, is awaiting congressional approval, which would replace the 2017 Farm Bill, which expires on September 30th. The full legalization of hemp would open the door for investment and provide access to a full range of financial, market development and advisory services that have been unavailable because of its classification as a controlled substance. These services would include small business loans (SBA’s), federal crop insurance, access to banking, USDA research.
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California and Washington State, Nevada, Italy, Jamaica and a joint venture on West Hollywood and San Bernardino dispensary applications. CROP has developed a portfolio of assets including Canna Drink a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, Life Sciences, Medical Marijuana, News Home
DIAGNOS to Provide Retinal Image Analysis using its AI Technology to 20/20NOW, the Leading Ocular Telehealth Provider in the United States
Momentum Public Relations
Press Release: September 18, 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today a three-year agreement to provide its CARA (Computer Assisted Retina Analysis) to 20/20NOW. 20/20NOW will use CARA to upload their retinal images and retrieve the results after analysis by our algorithms to detect anomalies caused by diabetic retinopathy in real time. Identifying diabetic retinopathy (“DR”) in its early stages, when it’s most treatable, is critical to prevent blindness and help at lowering health care costs.
“At DIAGNOS, we’re pleased to welcome an innovative company, 20/20NOW, as a new customer and business partner. We also want to extend a warm welcome to their network of more than 60 customers located across the United States. We will exclusively provide rapid and early detection of DR to their customers in the optical space. As 20/20NOW expands their network, we will provide them with fast and reliable detection of DR. As we introduce new healthcare applications, we will work with 20/20NOW to leverage their network and provide early detection of other illnesses to the benefit of their patients.” said Yves-Stephane Couture, Vice-President of Sales at DIAGNOS.
Telehealth industry veteran and 20/20NOW CEO, Chuck Scott, stated “Our mission at 20/20NOW is to expand access to comprehensive eye exams while also improving the standard of care, at a lower cost to our patients. Through the use of cutting-edge AI technology provided by DIAGNOS, our Ocular Telehealth eye exams represent a cost-effective tool to help solve one of the most pressing health care issue in our country today.”
Mr. Scott further stated “The opportunity exists to combine the use of AI and Ocular Telehealth to cost effectively screen and detect other critical health diseases beyond diabetic retinopathy. We believe there will be a vast array of ocular diseases that can be detected through AI and retinal screenings in the future. We look forward to partnering with DIAGNOS to bring these capabilities to market.”
About 20/20NOW
20/20NOW is the pioneer and innovator of ocular telehealth. Using state-of-the-art technology, proprietary software and patented exam processes, 20/20NOW provides comprehensive eye exams, including eye health screenings, via telehealth. The company’s telehealth model allows eye care professionals and optical retailers to provide their patients with increased access to high quality eye exams at a lower cost.
Additional information is available at www.for2020now.com.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com.
- Published in Business, Diagnos, Life Sciences, News Home, Technology
CROP Receives Permit to Complete Construction at ‘The Dozen’ Greenhouse Project in Washington
Momentum Public Relations
Press Release: September 18, 2018
CROP Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) announced today that it has received an updated building permit for its Washington “The Dozen” Project. CROP had previously revised the building plans to include upgraded access roads and a new staff facility, including restroom and break-room.
The company has completed 90% of the construction of the first six (6) purpose-built proprietary greenhouses and will now complete the final construction for site approval.
Phase one of construction, consisted of site preparation and foundations for twelve (12) purpose-built indoor agricultural canopies encompassing a planned total area of approximately 44,000 square feet.
Each completed phase will be leased to licensed tenant growers along with brand licensing and the CROP SAFE Standard Operating Procedures (SOPs). The site currently allows for about 176,000 square feet of canopy space.
The 12 indoor growing facilities will benefit from a regional electricity rate of $0.02/kWh USD and based on internal calculations provided by CROP’s expert consulting partner, should result in tenant cost of production of less than $150.00 USD per lb. ($0.33 per gram) with adherence to the CROP SAFE Standard Operating Procedures.
CROP Infrastructure Director and CEO, Michael Yorke, stated: “Once the project is completed this will serve as our CROP SAFE production model for all our future builds across the globe. We intend to have strict replication of our growing procedures to get the best return from every square foot of growing space and the lowest cost possible for our tenants.”
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California and Washington State, Nevada, Italy, Jamaica and a joint venture on West Hollywood and San Bernardino dispensary applications. CROP has developed a portfolio of assets including Canna Drink a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, Medical Marijuana, News Home
CROP’s California Harvest Passes Test
Momentum Public Relations
Press Release: September 14, 2018
CROP Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (“CROP”)announced today its California tenant has received lab result from its first crop. The first sample of dried BOSS OG Cannabis flower was submitted to Humboldt Quality Assurance Laboratory for analysis on August 27, 2018.
The sample has received a Tetrahydrocannabolic Acid (‘THCA’) result of 21.4% and passed all tests for microbial impurities and it also had no detectable pesticides. THCA is not directly used, but its presence is commonly analyzed when cannabis or hemp-based products are screened for THC. Samples have now been submitted for State testing for the approval to sell.
The third greenhouse crop has now been harvested and is drying. The company is awaiting construction permits to buildout 12 propriety light supplemented greenhouses totaling 44,000 sq. ft.
CROP Infrastructure Director and CEO, Michael Yorke, stated: “CROP’s tenant has strictly adhered to the CROP SAFE gold standard for organic cannabis cultivation practices. CROP SAFE utilizes only natural ingredients for its fertilizers and pest control. Once CROP completes its green house complex we can anticipate considerably increased production from this tenanted facility.”
About CROP
CROP Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California and Washington State, Nevada, Italy, Jamaica and a joint venture on West Hollywood and San Bernardino dispensary applications. CROP has developed a portfolio of assets including Canna Drink a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, Medical Marijuana, News Home
Crop Developing Cannadrink CBD-Infused Beverages
Momentum Public Relations
Press Release: September 13, 2018
CROP Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) announced today it is developing a new cannabis-infused line of soft drinks. Called ‘CANNADRINK’, the beverage will be developed to be a zero calorie, non-GMO, ketogenic-friendly line of soda pop, and will include tea and coffee versions.
The global carbonated soft drinks market is projected to reach USD 605.6 Billion by 2025, according to a March 2018 report by Grand View Research, Inc.
CROP Infrastructure Director and CEO, Michael Yorke, stated: “The cannabis-infused beverages market has attracted the attention of world class beverage companies as legalization spreads. We see it as a tremendous opportunity for CROP Infrastructure’s branding & IP portfolio and as an axillary opportunity for each of our cultivation tenants Globally.
“The global soft drink market, in another study, is forecast to grow at a CAGR of 5.62% through to 2021. It is also going sugar free. Studies from the World Health Organization have shown that a simple can of carbonated soda drink can contain over 40 grams of sugar, equivalent to 10 teaspoons of table sugar. As an example, Britain’s sugar tax has forced many soft drinks companies to re-evaluate the sugar content of their soft drinks and are developing new low or reduced-sugar beverages with additional claimed health benefits, in response to consumer demand.
“Functional beverages are a new class of products that offer beyond basic nutritional ingredients including vitamins, minerals, herbs, amino acids and probiotics. We believe that cannabis’s medically known benefits will enhance our own formulations, so we are bang on target with our CANNA DRINK line,” concluded Yorke.
Follow CannaDrink on Instagram & Twitter.
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California and Washington State, Nevada, Italy, Jamaica and a joint venture on West Hollywood and San Bernardino dispensary applications. CROP has developed a portfolio of assets including Canna Drink a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: http://www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, Medical Marijuana, News Home
Health Canada Reclassifies Tetra Bio-Pharma’s Inhalation Device Making it Eligible for Reimbursement
Momentum Public Relations
Press Release: September 13, 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that Health Canada has re-classified the inhalation pipe device used in the delivery of its PPP001 cannabis drug to a Class 2 Medical Device. The reclassification will help pave the way towards reimbursement for patients; a key element to patient access and care. The significance of this decision is such that if PPP001 is approved by Health Canada, both the prescription drug and the inhalation device will be eligible for insurance coverage by private and provincial public insurance plans. Tetra Bio-Pharma is undertaking a Phase III trial with PPP001 treating late stage cancer patients looking to improve quality of life and reduce pain. The Company also recently announced it is starting a head to head trial to investigate cannabis versus Fentanyl in managing breakthrough cancer pain.
“We are very excited by the reclassification as we believe it will provide patients with a financial benefit in terms of coverage for the device and prescription drug,” stated Dr. Guy Chamberland, Ph.D., Interim CEO and CSO at Tetra Bio-Pharma. “Many cancer patients rely on private and public insurance plans for access to their medication. This decision by the Government of Canada is an important step forward to facilitating access to cannabis drugs. This coupled with our robust clinical trial program and the evidence we are establishing will support physicians in discussing and recommending this option with their patients.”
Dr. Chamberland further stated, “the lack of scientific data on the safety and efficacy of cannabis is a critical barrier to patient access, and something that Canadian physicians are waiting for before being comfortable to prescribe it. Equally essential is adhering to the highest standards of drug manufacturing as well as the production of the delivery mechanism – something that Tetra is committed to. There are more than 300,000 registered users of medical cannabis in the country and we can only expect this number to rise.”
Tetra has been a pioneer in the development of several cannabis drugs. To date, the Corporation has completed several safety and pharmacokinetic studies in healthy volunteers obtaining proper dosing information and a clear understanding of the potential cardiovascular and neurological risks to patients. This information is critical to protect public health, and Tetra Bio-Pharma is engaged with Health Canada to comply with the highest drug safety standards.
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
- Published in Business, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Crop Completes Purchase of Nye County Farm
Momentum Public Relations
Press Release: September 7, 2018
CROP Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (“CROP“ or the “Company“) announced today that it has completed the member interest purchase agreement with Elite Ventures LLC, of Nevada, to acquire a 49% member interest in the Nye County agricultural property. The company has agreed to pay $1,350,000 USD in cash and has currently loaned $1,697,148 USD for the property and equipment expenses, with no more than $200,000 in additional expenses expected for this first harvest.
The Nye County agricultural property is in central Nevada and was selected for its temperate climate which is ideal for greenhouse and outdoor growing. The property totals over 315 acres and includes 300 acres of private water rights, with 240 acres under automatic irrigation pivots that also have automatic fertilizer injection systems installed.
The previously announced 240 acres of CBD Hemp has been planted and is currently 2.5-3 feet tall and growing under pivot with the resulting harvest expected within 45 days. A recent plant count suggests 3,000 healthy plants per acre or 720,000 plants under pivot. All harvesting equipment has been secured for the resulting hemp biomass. The cost of production was not expected to exceed $700,000, with $350,000 incurred to date, and no more then $200,000 in additional costs expected to prepare our tenant for this harvest.
CROP Infrastructure Director and CEO, Michael Yorke, stated: “We are pleased to have completed this acquisition and see our operations coming in under budget for this first harvest. This further demonstrates that our tenant and brand licensee was the correct choice for our Nevada farm. The next phase of development will be a state-of-the-art extraction facility to make high-value CBD isolate.”
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California and Washington State, Nevada, Italy, Jamaica and a joint venture on West Hollywood and San Bernardino dispensary applications. CROP has developed a portfolio of 16 Cannabis brands and has US and Italian distribution rights to a line of over 55 cannabis topical products from The Yield Growth Corp.
- Published in Business, CROP Infrastructure, Medical Marijuana, News Home, Uncategorized